Literature DB >> 15351702

Chronic administration of NMU into the paraventricular nucleus stimulates the HPA axis but does not influence food intake or body weight.

Emily L Thompson1, Kevin G Murphy, Jeannie F Todd, Niamh M Martin, Caroline J Small, Mohammad A Ghatei, Stephen R Bloom.   

Abstract

Hypothalamic neuromedin U (NMU) appears to have a role in the regulation of appetite and the hypothalamo-pituitary-adrenal (HPA) axis. Acute administration of NMU into the paraventricular nuclei (iPVN) increases plasma adrenocorticotrophic hormone and corticosterone, and inhibits food intake in fasted rats. No studies have as yet investigated the chronic effects of centrally administered NMU. We investigated the effect of twice-daily iPVN injections of 0.3 nmol NMU for 7 days on food intake, body weight, the HPA axis, and behavior in freely fed rats. Chronic iPVN NMU was not associated with a decrease in food intake or body weight. Chronic iPVN NMU produced a typical behavioral response on day 1 and day 4 of the study, and resulted in the elevation of plasma corticosterone present 18 h after the final injection. These results suggest NMU may have a role in the regulation of the HPA axis and behavior. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15351702     DOI: 10.1016/j.bbrc.2004.08.058

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  12 in total

1.  Neuromedin S and U.

Authors:  Colleen M Novak
Journal:  Endocrinology       Date:  2009-07       Impact factor: 4.736

2.  Common variants at 5q33.1 predispose to migraine in African-American children.

Authors:  Xiao Chang; Renata Pellegrino; James Garifallou; Michael March; James Snyder; Frank Mentch; Jin Li; Cuiping Hou; Yichuan Liu; Patrick M A Sleiman; Hakon Hakonarson
Journal:  J Med Genet       Date:  2018-09-28       Impact factor: 6.318

Review 3.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

Review 4.  Regulation of appetite to treat obesity.

Authors:  Gilbert W Kim; Jieru E Lin; Michael A Valentino; Francheska Colon-Gonzalez; Scott A Waldman
Journal:  Expert Rev Clin Pharmacol       Date:  2011-03       Impact factor: 5.045

5.  Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding.

Authors:  Hongkui Zeng; Alexander Gragerov; John G Hohmann; Maria N Pavlova; Brian A Schimpf; Hui Xu; Long-Jun Wu; Hiroki Toyoda; Ming-Gao Zhao; Alex D Rohde; Galina Gragerova; Rene Onrust; John E Bergmann; Min Zhuo; George A Gaitanaris
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

6.  Current trends in targeting the hormonal regulation of appetite and energy balance to treat obesity.

Authors:  Michael A Valentino; Francheska Colon-Gonzalez; Jieru E Lin; Scott A Waldman
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 7.  Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S.

Authors:  J D Mitchell; J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

8.  The antiobesity effects of centrally administered neuromedin U and neuromedin S are mediated predominantly by the neuromedin U receptor 2 (NMUR2).

Authors:  Andrea Peier; Jennifer Kosinski; Kimberly Cox-York; Ying Qian; Kunal Desai; Yue Feng; Prashant Trivedi; Nicholas Hastings; Donald J Marsh
Journal:  Endocrinology       Date:  2009-03-26       Impact factor: 4.736

9.  Sensitivity of the hypothalamic paraventricular nucleus to the locomotor-activating effects of neuromedin U in obesity.

Authors:  Colleen M Novak; Minzhi Zhang; James A Levine
Journal:  Brain Res       Date:  2007-07-13       Impact factor: 3.252

10.  Differential effects of selective agonists of neuromedin U1 and U2 receptors in obese and diabetic mice.

Authors:  Hiroaki Nagai; Tomoko Kaisho; Kotaro Yokoyama; Tomoko Asakawa; Hisashi Fujita; Kouta Matsumiya; Jiro Noguchi; Kazue Tsuchimori; Naoki Nishizawa; Yoko Kanematsu-Yamaki; Katsuko Dote; Hiroshi Inooka; Jun-Ichi Sakamoto; Tetsuya Ohtaki; Taiji Asami; Shiro Takekawa
Journal:  Br J Pharmacol       Date:  2017-12-18       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.